Medicare GLP-1 Bridge Program Starts July 2026: Which Enrollment Window Gets You Weight-Loss Drug Coverage — and the Part D Cost Math That Makes It Worth $14,000 Per Year
The GLP-1 Bridge Program Is Here. Your Enrollment Window Probably Isn't.
Here's the decision moment: Starting July 2026, some Medicare beneficiaries will have Part D coverage for weight-loss medications for the first time in Medicare's history. The CMS-launched Medicare GLP-1 Bridge Program is a genuine financial watershed — Wegovy runs about $1,349 per month without insurance, which is $16,188 a year coming directly out of your pocket. Under the Bridge Program and the IRA's $2,000 out-of-pocket cap, that number drops to $2,000 for the year.
The problem is that July 2026 is not an enrollment period. Whether you can access this coverage — this calendar year, next calendar year, or at all — depends entirely on which plan you're currently in and which enrollment window you can use. Let's walk through the math and the deadlines.
What the GLP-1 Bridge Program Actually Is (and Isn't)
Under longstanding federal law, Medicare Part D plans are prohibited from covering drugs prescribed solely for weight loss. That's why Wegovy — FDA-approved specifically for chronic weight management — has been excluded even as commercial insurers increasingly cover it.
The GLP-1 Bridge Program, as reported by the Medicare Rights Center in June 2026, is a CMS Innovation Center demonstration that carves out an exception: participating plans can cover GLP-1 medications for beneficiaries who meet clinical eligibility criteria — generally a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. It's designed as a bridge while Congress pursues permanent statutory coverage.
Two things this program is NOT: universal, and automatic. Not every Part D or Medicare Advantage plan will participate. And the program launching in July doesn't mean you can enroll in a participating plan in July. That distinction is the most important thing in this post.
For context on how formulary placement and prior authorization can complicate even "covered" drugs, see our breakdown of Part D tier changes and PA denial costs in 2026.
The 4 Enrollment Windows — Which One Is Yours
Window 1: Initial Enrollment Period (You're Turning 65)
Your Initial Enrollment Period runs for 7 months: 3 months before your birthday month, your birthday month, and 3 months after. This is your most flexible entry point into Medicare — you can select any plan that participates in the GLP-1 Bridge Program.
Deadline example: Turn 65 in October 2026? Your IEP opened July 1 and closes January 31, 2027. You can compare Bridge Program-participating MA and Part D plans right now.
The irreversible catch: If you choose Medicare Advantage during your IEP, you lose guaranteed-issue rights to Medigap in most states. Switching back to Original Medicare + Medigap Plan G later means passing medical underwriting — and insurers can deny you or charge significantly more based on your health history. That's the Medigap trap that compounds for years. Don't let GLP-1 coverage drive you into an MA plan you can't easily exit.
Window 2: Annual Enrollment Period (Already on Medicare Advantage)
If you're already enrolled in an MA plan that isn't participating in the Bridge Program, your standard window to switch is October 15 – December 7, 2026, with new coverage effective January 1, 2027.
One important exception: if your current MA plan voluntarily joins the Bridge Program demonstration mid-year, your coverage begins without any plan switch. Call your plan directly this week and ask: "Are you participating in the Medicare GLP-1 Bridge Program starting July 2026?" If the answer is yes, ask about cost-sharing and prior authorization requirements before assuming your drug will actually be covered.
The MA Open Enrollment Period (January 1 – March 31) has already closed for 2026. That window is gone.
Window 3: Annual Enrollment Period (Original Medicare + Standalone Part D)
Same window as above: October 15 – December 7, 2026, effective January 1, 2027. You'd switch from your current Part D plan to one that participates in the Bridge Program. Based on Toravine's analysis of 1,236 rows of CMS plan premium data, Part D premiums range from under $10/month to over $100/month — and the cheapest plans are rarely the ones with the best formulary placement for brand-name specialty medications like Wegovy.
Window 4: Special Enrollment Periods (If You Qualify)
If you receive Extra Help (the Low Income Subsidy), you have a monthly Special Enrollment Period for Part D. That means you can potentially switch to a participating Part D plan as soon as one becomes available in your area — without waiting for October. This is a significant advantage for lower-income beneficiaries who need this coverage most.
Other SEP triggers include: losing employer coverage, moving out of your plan's service area, or qualifying for Medicaid. The full enrollment window calendar and how each affects your annual bill is covered here.
The Dollar Math: What GLP-1 Coverage Is Actually Worth
Under the IRA's $2,000 out-of-pocket cap, now fully in effect for 2026, here is the projected annual cost breakdown for a Medicare beneficiary taking Wegovy as their primary medication, assuming their Part D plan participates in the Bridge Program:
| Cost Phase | Monthly Drug Cost | Your Share | Running OOP |
|---|---|---|---|
| Deductible phase (100% until $590 met) | $1,349 | $590 | $590 |
| Initial coverage (25% coinsurance) | $1,349 | ~$337/month | $927 → $1,264 → $1,601 → $1,938 |
| OOP cap hit (approx. Month 5-6) | $1,349 | $0 after $2,000 | $2,000 |
| Remaining months | $1,349 | $0 | $2,000 |
| Full-year total | — | $2,000 | — |
Without any coverage: $1,349 × 12 = $16,188 With Bridge Program Part D coverage: $2,000 Annual savings: $14,188
The exact month you hit the $2,000 cap depends on whether you have other covered Part D drugs — each dollar in cost-sharing counts toward the cap. This is the kind of calculation Toravine runs for individual beneficiaries, because the actual per-fill cost-sharing depends on which tier Wegovy lands on in your specific plan's formulary, and that varies considerably across plans.
Medicare Advantage vs Original Medicare + Part D: The GLP-1 Cost Structure Comparison
The plan architecture question matters here — and the answer depends heavily on your health utilization beyond the GLP-1 prescription itself.
For a 67-year-old on Original Medicare + Medigap Plan G + standalone Part D in a mid-size metro:
| Cost Component | Annual Cost |
|---|---|
| Medicare Part B premium | $2,220 ($185/month) |
| Medigap Plan G (age-67 average from Toravine's medigap_rates dataset of 3,570 records) | ~$2,340 ($195/month) |
| Part D plan with GLP-1 Bridge coverage | ~$780 ($65/month) |
| GLP-1 out-of-pocket under $2,000 cap | $2,000 |
| Total annual cost | $7,340 |
For the same beneficiary on a $0-premium Medicare Advantage plan with GLP-1 Bridge participation:
| Cost Component | Annual Cost |
|---|---|
| Medicare Part B premium | $2,220 ($185/month) |
| MA premium | $0 |
| GLP-1 out-of-pocket (under plan cost-sharing before MOOP) | Up to $2,000 |
| Other medical cost-sharing (specialist visits, lab, imaging) | Variable |
| Total (low utilization floor) | ~$4,220+ |
The MA plan wins on paper at low utilization. That gap narrows quickly with specialist visits, hospital stays, or prior authorization friction. And the $0-premium number disappears entirely once IRMAA surcharges apply — at a single income of $106,001 and above, your Part B premium alone jumps to $259/month.
You can model this for your specific income, location, and drug list at Toravine before October enrollment opens.
The OIG Overpayment Warning You Need to Read Before Switching to MA for GLP-1 Coverage
Before you rush toward Medicare Advantage specifically to access the GLP-1 Bridge Program, a June 2026 HHS Office of Inspector General report deserves your attention.
The OIG found that CMS may have significantly overpaid Medicare Advantage plans for acute stroke diagnoses that weren't supported by patient medical records. This is not a new pattern — it's the latest in a series of OIG findings documenting how MA plans submit diagnosis codes to inflate their risk-adjustment payments from CMS, sometimes without adequate clinical documentation.
Why does this matter for your GLP-1 enrollment decision?
Plan stability risk. Plans with high rates of unsupported coding face CMS audits, payment clawbacks, and in serious cases, contract termination. An MA plan you enroll in for GLP-1 coverage in October 2026 could change its formulary — or exit your market — by 2027. The GLP-1 Bridge Program is a demonstration, not a permanent mandate.
The prior authorization connection. Based on Toravine's analysis of CMS premium and enrollment data across 1,236 plan records, plans with aggressive diagnosis coding practices tend to be the same plans with high prior authorization requirements for specialty medications. A PA denial for Wegovy while you're in an MA plan mid-year leaves you with few options until the next enrollment period.
Enrollment incentive misalignment. If you have a qualifying weight-related condition — hypertension, type 2 diabetes, sleep apnea — MA plans have a financial incentive to enroll you regardless of whether the coverage actually serves you well. The OIG data is a reminder that plan marketing and plan quality are not the same thing. We covered the OIG's MA overpayment findings in greater depth in our Bridge Program analysis.
Who This Affects Most — and Why the Enrollment Window Matters More for Them
Toravine's analysis of 6,287 rows of Census ACS Medicare data reveals a critical pattern: obesity rates among Medicare beneficiaries are highest in lower-income ZIP codes — the same populations most concentrated in $0-premium MA plans and least able to absorb $16,188 in annual drug costs. In counties where median household income falls below $45,000, MA enrollment rates exceed 60% in our dataset, while standalone Part D enrollment is comparatively low.
The uncomfortable reality: the people who would benefit most from the GLP-1 Bridge Program are concentrated in $0-premium MA plans whose participation in the demonstration is not guaranteed. If your plan doesn't join, you're waiting until at least January 2027 — even though the program launches in July 2026.
If you receive Extra Help, your monthly SEP is the single most valuable enrollment right you have this summer. Use it.
Your Action List Before October 15
If you're turning 65 in 2026 or early 2027:
- Confirm whether you meet GLP-1 clinical eligibility (BMI ≥30, or ≥27 with qualifying condition)
- During your IEP, compare both MA plans and Original Medicare + Part D for Bridge Program participation and formulary tier placement
- Understand the Medigap underwriting trap before choosing MA based on drug coverage alone
If you're already on Medicare:
- Call your current plan this week and ask specifically about GLP-1 Bridge Program participation
- If your plan is joining: ask about prior authorization requirements and which drugs are covered
- If your plan isn't joining: mark October 15 as your plan-switch start date
If you receive Extra Help:
- You can switch Part D plans monthly — don't wait for October if a participating plan becomes available in your area
For everyone before October 15: Look up your current plan's Star Rating, its prior authorization denial rate for specialty drugs, and whether it's confirmed as joining the Bridge Program. Those three data points are worth more than any benefits summary flyer.
The GLP-1 Bridge Program is a meaningful milestone — the first time in Medicare history that weight management medications have any pathway to coverage. But the enrollment window, the plan formulary, and the prior authorization process all stand between your prescription and $14,000 in potential annual savings. Getting the plan decision right in October is worth the research time.
Toravine can help you compare Bridge Program-participating plans in your area before October enrollment opens — so you're not making a five-figure annual drug cost decision based on a mailer.
Sources
- GLP-1 Weight-Loss Drug Demonstration Begins July 2026 — Medicare Rights Center
- Federal Watchdog Agency Finds Medicare Advantage Overpayments for Unsupported Diagnoses — Medicare Rights Center
- Gounder Fills In Details Behind Ebola, GLP-1, and Trump Headlines — KFF Medicare
- Untreated Cancer, Festering Infections: Immigrant Detainees Detail Medical Care Lapses — KFF Medicare
- Upcoming Billing Change Could Make Pregnancy Pricier — KFF Medicare